Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Gupta

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Indian Journal of Ophthalmology|July 30, 2024
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study groupManisha Agarwal, Alankrita Muralidhar, Mahesh P Shanmugam, et al.
Circulation|August 10, 2016
Palliative Care and Cardiovascular Disease and Stroke: A Policy Statement From the American Heart Association/American Stroke AssociationLynne T Braun, Kathleen L Grady, Jean S Kutner, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Indian Journal of Ophthalmology|December 2, 2024
Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world studyDeependra Vikram Singh, Aniruddha Agarwal, Anubhav Goyal, et al.
Environmental Microbiology|November 19, 2013
Halomonas sulfidaeris-dominated microbial community inhabits a 1.8 km-deep subsurface Cambrian Sandstone reservoirYiran Dong, Charu Gupta Kumar, Nicholas Chia, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Indian Journal of Ophthalmology|July 30, 2024
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study groupManisha Agarwal, Alankrita Muralidhar, Mahesh P Shanmugam, et al.
Circulation|August 10, 2016
Palliative Care and Cardiovascular Disease and Stroke: A Policy Statement From the American Heart Association/American Stroke AssociationLynne T Braun, Kathleen L Grady, Jean S Kutner, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Indian Journal of Ophthalmology|December 2, 2024
Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world studyDeependra Vikram Singh, Aniruddha Agarwal, Anubhav Goyal, et al.
Environmental Microbiology|November 19, 2013
Halomonas sulfidaeris-dominated microbial community inhabits a 1.8 km-deep subsurface Cambrian Sandstone reservoirYiran Dong, Charu Gupta Kumar, Nicholas Chia, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Pageof 7